Osteo-Adapt SP is a regenerative implant indicated for transforaminal lumbar interbody spinal fusion. It’s intended to treat degenerative disc disease, spondylolisthesis and retrolisthesis. Theradaptive’s implants are designed to allow precise tissue regeneration.
“Theradaptive has developed a technology that may provide several significant advantages over the current state-of-the-art in spinal fusion and musculoskeletal repair, including greater safety and more consistent outcomes,” George Muschler, MD, of Cleveland Clinic, said in the release.
Under breakthrough designation, the product will receive priority review and interactive communications on device development from the FDA.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.